Agalimmune: Agalimmune Limited Licenses FSL Technology For Development Of Cancer Immunotherapeutics
Deal worth up to $31M USD (21 million GBP)LONDON--(www.businesswire.com/">BUSINESS WIRE)--Agalimmune Ltd, a biopharmaceutical company focused on the development of a pipeline of innovative...
Read full article »
Agalimmune focuses on developing an anti-cancer immunotherapy technology for the treatment of patients with solid tumors.
Read more